BC
Therapeutic Areas
Maxwell Biomedical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rhythm360 / CRT-A | Atrial Fibrillation in patients with Heart Failure with Preserved Ejection Fraction (AF-HFpEF) and Post-Cardiac Surgery AF | Pre-clinical |
Leadership Team at Maxwell Biomedical
RW
Randy Werneth
CEO, President
TC
Timothy Corvi
Sr. VP, R&D
DC
Derrick Chou, PhD
VP, Science & Technology
WB
Walter Bomela, PhD
Dynamical Systems Scientist
JC
J. Chris Flaherty
IP Strategist
RÓ
Ragnar Ólafsson, PhD
Sr. Principal Systems Engineer